IN2014MN01560A - - Google Patents

Info

Publication number
IN2014MN01560A
IN2014MN01560A IN1560MUN2014A IN2014MN01560A IN 2014MN01560 A IN2014MN01560 A IN 2014MN01560A IN 1560MUN2014 A IN1560MUN2014 A IN 1560MUN2014A IN 2014MN01560 A IN2014MN01560 A IN 2014MN01560A
Authority
IN
India
Prior art keywords
crystalline forms
quinazolin
difluorophenyl
triazol
chloro
Prior art date
Application number
Other languages
English (en)
Inventor
Antonio Canovas Paredes
Javier Bartroli Orpi
Elies Molins Grau
Anna Roig Serra
Kevin Meyer
Keith Lorimer
Original Assignee
Palau Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39082545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014MN01560(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06380225A external-priority patent/EP1887004A1/de
Priority claimed from EP07380186A external-priority patent/EP2009009A1/de
Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa
Publication of IN2014MN01560A publication Critical patent/IN2014MN01560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1560MUN2014 2006-08-07 2007-08-06 IN2014MN01560A (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83586306P 2006-08-07 2006-08-07
EP06380225A EP1887004A1 (de) 2006-08-07 2006-08-07 Kristalline Formen von (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]chinazolin-4(3H)-on
US92940807P 2007-06-26 2007-06-26
EP07380186A EP2009009A1 (de) 2007-06-26 2007-06-26 Antifungale Kristallverbindungen
PCT/US2007/017476 WO2008021049A2 (en) 2006-08-07 2007-08-06 Crystalline antifungal compounds

Publications (1)

Publication Number Publication Date
IN2014MN01560A true IN2014MN01560A (de) 2015-05-08

Family

ID=39082545

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1560MUN2014 IN2014MN01560A (de) 2006-08-07 2007-08-06

Country Status (17)

Country Link
US (2) US7879867B2 (de)
EP (2) EP2049504A4 (de)
JP (3) JP2010513222A (de)
KR (1) KR20090053903A (de)
CN (1) CN103232442B (de)
AR (1) AR062232A1 (de)
AU (1) AU2007284851B2 (de)
BR (1) BRPI0716026A2 (de)
CA (1) CA2658843A1 (de)
DK (1) DK2650291T3 (de)
ES (1) ES2652670T3 (de)
IL (2) IL196722A (de)
IN (1) IN2014MN01560A (de)
MX (1) MX2009001208A (de)
RU (1) RU2500679C2 (de)
TW (1) TWI426073B (de)
WO (1) WO2008021049A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
TWI363058B (en) * 2006-04-05 2012-05-01 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
ITMI20062449A1 (it) * 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
AU2010254064B2 (en) * 2009-05-29 2015-01-22 Palau Pharma, S.L.U Azole antifungal compositions
KR20120079054A (ko) * 2009-07-10 2012-07-11 에볼바 아게 디인 조성물
EP2464230B1 (de) * 2009-08-14 2016-10-05 OPKO Health, Inc. Intravenöse formulierungen von rolapitant
US9435692B2 (en) 2014-02-05 2016-09-06 Lam Research Corporation Calculating power input to an array of thermal control elements to achieve a two-dimensional temperature output
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
EA025187B1 (ru) * 2015-04-17 2016-11-30 Тагир Аббасели оглы Сулейманов Производное дитиокарбамата 2-((4-(4-метилпиперазин-1-ил)фенил)амино)-2-оксоетил4-этилпиперазин-1-карбодитиоат, обладающее антифунгальной активностью
CN118695852A (zh) 2021-12-22 2024-09-24 帕劳制药有限公司 多颗粒阿巴康唑组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0293500A1 (de) 1987-06-01 1988-12-07 American Cyanamid Company 3-Heteroalkyl-2,4-quinazolinedione, 3-Heteroaryl-1,2,3-benzotriazin-4(3H)-one, 3-Heteroarylalkyl-4-quinazolinon
GB8819308D0 (en) 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
TW218017B (de) 1992-04-28 1993-12-21 Takeda Pharm Industry Co Ltd
TW297813B (de) * 1993-09-24 1997-02-11 Takeda Pharm Industry Co Ltd
CA2134417A1 (en) * 1993-12-22 1995-06-23 Katsumi Itoh Optically active azole derivatives, their production and use
MX9702382A (es) * 1995-08-02 1998-02-28 Uriach & Cia Sa J Nuevos derivados de pirimidona con actividad antifungica.
WO1998039305A1 (en) * 1997-03-05 1998-09-11 Takeda Chemical Industries, Ltd. Crystalline form of a bis 1,2,4-triazole compound
ES2159488B1 (es) * 2000-03-07 2002-04-16 Uriach & Cia Sa J Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica.

Also Published As

Publication number Publication date
AU2007284851A1 (en) 2008-02-21
US7879867B2 (en) 2011-02-01
JP2010513222A (ja) 2010-04-30
TWI426073B (zh) 2014-02-11
US20110092702A1 (en) 2011-04-21
EP2650291A1 (de) 2013-10-16
RU2500679C2 (ru) 2013-12-10
IL196722A (en) 2016-10-31
CA2658843A1 (en) 2008-02-21
WO2008021049A2 (en) 2008-02-21
EP2049504A4 (de) 2010-09-22
EP2650291B1 (de) 2017-10-04
AR062232A1 (es) 2008-10-22
JP2014012673A (ja) 2014-01-23
IL248216B (en) 2018-03-29
WO2008021049A9 (en) 2008-10-30
EP2049504A2 (de) 2009-04-22
TW200823197A (en) 2008-06-01
RU2009104959A (ru) 2010-08-20
WO2008021049A3 (en) 2008-12-31
IL196722A0 (en) 2009-11-18
ES2652670T3 (es) 2018-02-05
US8258296B2 (en) 2012-09-04
DK2650291T3 (en) 2017-10-23
MX2009001208A (es) 2009-04-14
KR20090053903A (ko) 2009-05-28
CN103232442A (zh) 2013-08-07
CN103232442B (zh) 2015-01-21
AU2007284851B2 (en) 2013-05-09
US20080076787A1 (en) 2008-03-27
BRPI0716026A2 (pt) 2013-08-06
JP2015193642A (ja) 2015-11-05

Similar Documents

Publication Publication Date Title
WO2008021049A3 (en) Crystalline antifungal compounds
ATE534632T1 (de) Thiazole, imidazole und pyrazole als proteinkinasehemmer
EP2476679A3 (de) Substituierte Triazole als AXL-Hemmer
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
EP2484679A3 (de) N3-heteroaryl substituierte Triazole und N5-heteroaryl-substituierte Triazole, die als AXL-Hemmer nützlich sind
SG166828A1 (en) Aminopyrimidines useful as kinase inhibitors
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
MX2009009591A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008147626A3 (en) Thiazoles and pyrazoles useful as kinase inhibitors
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
TW200714604A (en) Substituted heterocycles and the uses thereof
EP3037421A3 (de) Mlk-hemmer und verfahren zur verwendung
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
JO3134B1 (ar) مثبطات نشاط akt
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
WO2007059202A3 (en) Pyrazolyl urea derivatives useful in the treatment of cancer
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
EA200802129A1 (ru) 6-о-замещенные бензоксазолы и бензотиазолы и способы подавления передачи сигналов от csf-1r
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2009005231A (es) Composiciones utiles como inhibidores de proteina cinasa.